UNITED ~~STATES~~STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

~~SECURITIES AND~~Form ~~EXCHANGE COMMISSION~~ 6-K

~~Washington,~~REPORT ~~D.C.~~OF ~~20549~~FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-41923

EUPRAXIA PHARMACEUTICALS INC.(Exact name of Registrant as specified in its charter)

N/A(Translation of ~~registrant~~Registrant’s name ~~into English~~)

2198 Yukon ~~Street~~StreetVancouver, British Columbia, Canada V5Y 3P1Telephone: (250) 590-3968 (Address and telephone number of registrant’s principal executive office)

~~Vancouver,~~Indicate ~~British~~by ~~Columbia,~~check ~~Canada~~mark ~~V5Y~~whether ~~3P1~~the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.Form 20-F [ ] Form 40-F [ X ]

Telephone: (250) 590-3968

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☐ Form 40-F ☒

INCORPORATION BY REFERENCE

Exhibits 99.1 and 99.2 of this Form 6-K are incorporated by reference into the registrant’s Registration Statement on Form F-10 (File No. 333-276586) and the registrant’s Registration Statement on Form S-8 (File No. 333-278534).

DOCUMENTS INCLUDED AS PART OF THIS REPORT

Exhibit
99.1		Consolidated Financial Statements for the three and nine months ended March 31, 2026.
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three months ended March 31, 2026.
99.3		Press Release, dated May 12, 2026.
99.4		Form 52-109F2 Certification of Interim Filings by CEO.
99.5		Form 52-109F2 Certification of Interim Filings by CFO.

Exhibit

99.1		Press Release dated May 28, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Eupraxia Pharmaceuticals Inc.

EUPRAXIA PHARMACEUTICALS INC.

Date: May 12, 2026

/s/ Alex Rothwell

Date: May 28, 2026

/s/ Alex Rothwell

Name: Alex Rothwell

~~Name: Alex Rothwell~~

Title: Chief Financial Officer

~~Title: Chief Financial Officer~~

Filing Compare · EUPRAXIA PHARMACEUTICALS INC.